Evidence mapPaperPMID 40102467Full record

Observational studyScientific reports2025

Construction of a machine learning-based interpretable prediction model for acute kidney injury in hospitalized patients.

Xiang Yu, WanLing Wang, RiLiGe Wu, XinYan Gong, YuWei Ji, Zhe Feng

Abstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiang YuFirst Medical Center of Chinese PLA General Hospital, Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases,Beijing Key Laboratory of Digital Intelligent TCM for the Preventionand Treatment of Pan-vascular Diseases,Key Disciplines of National Administration of Traditional Chinese Medicine(zyyzdxk-2023310), Beijing, 100853, China.
WanLing WangMedical Innovation Research Division, Chinese PLA General Hospital, Beijing, 100853, China.
RiLiGe WuMedical Innovation Research Division, Chinese PLA General Hospital, Beijing, 100853, China.
XinYan GongFirst Medical Center of Chinese PLA General Hospital, Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases,Beijing Key Laboratory of Digital Intelligent TCM for the Preventionand Treatment of Pan-vascular Diseases,Key Disciplines of National Administration of Traditional Chinese Medicine(zyyzdxk-2023310), Beijing, 100853, China.
YuWei JiFirst Medical Center of Chinese PLA General Hospital, Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases,Beijing Key Laboratory of Digital Intelligent TCM for the Preventionand Treatment of Pan-vascular Diseases,Key Disciplines of National Administration of Traditional Chinese Medicine(zyyzdxk-2023310), Beijing, 100853, China.
Zhe FengFirst Medical Center of Chinese PLA General Hospital, Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases,Beijing Key Laboratory of Digital Intelligent TCM for the Preventionand Treatment of Pan-vascular Diseases,Key Disciplines of National Administration of Traditional Chinese Medicine(zyyzdxk-2023310), Beijing, 100853, China. zhezhe_4025@126.com.

Funding

National Key Research and Development Program of China 2022YFC3602900
6 · The paper itself

Abstract

In this observational study, we used data from 59,936 hospitalized adults to construct a model. For the models constructed with all 53 variables, all five models achieved acceptable performance with the validation cohort, with the extreme gradient boosting (XGBoost) model showing the best predictive efficacy and stability (area under the curve (AUC), 0.9301). For the simpler models constructed with 39 significant variables screened by the random forest recursive feature elimination method, the XGBoost model also had the best performance (AUC, 0.9357). All the models showed significant net returns according to decision analysis curves, and the XGBoost model achieved the optimal results. In addition, the Shapley additive explanation (SHAP) importance matrices revealed that uric acid, colloidal solution, first creatinine value on admission, pulse and albumin represented the top five most important variables for both modeling strategies. With the external validation cohort based on 4022 hospitalized patients, the performance of all models declined, among which the Support vector machine (SVM) model showed the best predictive efficacy (AUC, 0.8230 and 0.8329), followed by the XGBoost model (0.8124 and 0.8316). Thus, our model can predict the occurrence and risk of acute kidney injury (AKI) up to 48 h in advance, enabling clinicians to assess the risk of AKI in hospitalized patients more accurately and intuitively and to develop necessary AKI management strategies.

Indexed as

Acute Kidney InjuryMachine LearningAdultAgedArea Under CurveFemaleHospitalizationHumansMaleMiddle AgedRisk FactorsSupport Vector Machine

Identifiers

PMID40102467
PMCPMC11920398

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.